Novartis Phase II Data for New Inhaled Combination Treatment (QVM149) Demonstrates Significant Improvements Over Current Standard-of-Care Inhaled Treatment
Basel, May 22, 2019 - Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol acetate, glycopyrronium bromide and mometasone furoate,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 22, 2019 Category: Pharmaceuticals Source Type: clinical trials
Mometasone Furoate Aqueous Nasal Spray vs Placebo and Flonase ® in Seasonal Allergic Rhinitis Patients (I94-001)
Condition: Rhinitis, Allergic, Seasonal Interventions: Drug: Mometasone furoate; Drug: Fluticasone propionate; Drug: Mometasone furoate placebo; Drug: Fluticasone propionate placebo Sponsor: Merck Sharp & Dohme Corp. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 20, 2019 Category: Research Source Type: clinical trials
Dose-Ranging Study of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (C95-161)
Condition: Rhinitis, Allergic, Seasonal Interventions: Drug: Mometasone furoate nasal spray; Drug: Beclomethasone dipropionate nasal spray; Drug: Placebo nasal spray; Drug: Chlorpheniramine maleate syrup Sponsor: Merck Sharp & Dohme Corp. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 19, 2019 Category: Research Source Type: clinical trials
